References
- Inwards D. J., Armitage J. O. Modern chemother-apeutic regimens in the management of aggressive non-Hodgkin lymphoma: can they be improved?. European Journal Cancer 1991; 27: 510–13, 4
- Cheson B. C. New chemotherapeutic agents for non-Hodgkin's lymphoma. Hematology/Oncology Clinics of North America 1991; 5: 1027–51
- Buzzoni R., Bajetta E., Valagussa P, et al. Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas. American Journal of Clinical Oncology 1988; 11: 100–3, 2
- Loeffler T. M., Weber F. W., Freund W, et al. Mitoxantrone, Vindesine and Dexamethasone in relapsed non-Hodgkin's lymphoma. ECCO-4 1987; 269: 1032
- Devaux Y., Coiffier B., Tilly H. Novantrone-based salvage chemotherapy for malignant lymphomas. A phase II study. ECCO-4 1987; 226: 1081
- Coltman C. A., Coltman T. M., Balcerak S P., et al. Mitoxantrone in refractory non-Hodgkin's lymphoma. A Southwest Oncology Group study. Seminars in Oncology 1984; 11: 50–3
- Gams R. A., Bryan S., Dukart G, et al. Mitoxantrone in malignant lymphoma. Inv. Nev. Drugs 1985; 3: 219–22
- Brusamolino E., Bertini M., Guidi S, et al. CHOP vs CNOP (N = Mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity. Haematologica 1988; 73: 217–22
- Guglielmi C., Gherlinzoni F., Amadori S, et al. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Haematologica 1989; 74: 563–9
- Mazza P., Bocchia M., Zanchini R, et al. MN (N = Novantrone) COP-B therapy in high and intermediate-grade non-Hodgkin's lymphoma: an alternative to MA (A = Adriamycin) COP-B?. Haematologica 1991; 76: 47–52
- Silver R. T., Case D. C., Wheeler R H., et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. Journal of Clinical Oncology 1991; 9: 754–61
- Ohnoshi T., Hayashi K., Ueoka H, et al. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone. Cancer Treatment Reviews 1987; 71: 639–41
- Vitolo U., Orsucci L., Bertini M, et al. Mitoxantrone, etoposide, cisplatin, and dexamethazone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma. Haematologica 1991; 76: 43–6
- Contu A., Olmeo N., Schintu G M., et al. 1989; 119–-22, Il mitoxantrone nei linfomi non-Hodgkin. I Linfomi non = Hodgkin dell'adul-to
- Chisesi T., Capnist G., Rancan L, et al. Impiego del mitoxantrone nella terapia dei linfomi non-Hodgkin: risultati di uno studio in fase II in monochemioterapia o in associazione. Atti del XXXII Congresso Nazionale délia Società Italiana di Ematologia (Roma, 1989). Tumori 1989; 75: 311
- Chisesi T., Rancan L., Capnist G. Etoposide, Cyclophosphamide, Mitoxantrone, and Prednisone (VEMP) in the treatment of non-Hodgkin's lymphomas: preliminary results of a phase III study. Abstract of the Fourth International Conference on Malignant Lymphoma. Lugano 1990; T84: 127
- Chisesi T., Capnist G., Ranean L, et al. Etoposide, ciclofosfamide, mitoxantrone e prednisone (VEMP) nella terapia dei linfomi non-Hodgkin. In Atti del 33d` Congresso délia Società Italiana di Ematologia. Verona 1991; 165: 203
- Santini G., Contu A., Porcellini A, et al. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the non-Hodgkin's lymphoma co-operative study group (NHLCSG). Haematologica 1991; 76: 485–90
- Chisesi T., Ranean L., Capnist G. Mitoxantrone-containing regimens in refractory or relapsed non-Hodgkin's lymphomas: results of a phase II study. Abstract of the Fourth International Conference on Malignant Lymphoma. Lugano 1990; 193: 130
- Hansen S. W., Nissen N. I., Hansen M M., et al. High activity of Mitoxantrone in previously untreated low-grade lymphomas. Cancer Chemother. Pharmacol. 1988; 22: 77–9
- Vorobiof D. A., Terblanche A. P. S., Falkson C I., et al. Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma. Oncology 1988; 45: 378–9